NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

dstock, this ph 2 trial you found appears to be the third Ph 2 we in-licensed from Roswell and uses their DCs, NOT our DCVax-L. Note the use of intra-tumoral administration mentioned in the NWBO PR on Roswell and also in the cllinical trial that starts 10/1/2024. DCVax-L is not administered intra-tumorally:

Here is what we now own, according to our PR:

The DC based therapies include versions with tumor antigens loaded into the DCs and versions for intra-tumoral administration without pre-loading of antigens. Phase 2 trials involving the licensed technologies for two different cancers opened for enrollment earlier this year and are currently under way, and a third Phase 2 trial for a third cancer is pending. The trials are fully funded by grant funding and are being conducted as investigator led trials. The Company does not anticipate having to provide any funding or undertake any operational role for these trials.

From the clinical trial:

Patients may also receive an autologous dendritic cells intratumorally on day 50.

Great find, dstock! Thank you for all your hard work.